The FDA has approved raloxifene (generic Evista) as of March 2014. Brand name Evista was first approved in 1997.
The generic pharmaceutical manufacturer of raloxifene, TEVA, will be granted marketing exclusivity for 180 days and will begin to ship raloxifene within the next 30 days.
Who and what is this medication for?
Raloxifene is indicated in postmenopausal women for the treatment and prevention of osteoporosis, and it reduces the risk of invasive breast cancer in women with osteoporosis or others who are at high risk.
Who should NOT use raloxifene?
Raloxifene should NOT be used in pregnant or breast-feeding women, or in women with a history of or with active venous thromboembolisms (AKA blood clots).
How is raloxifene usually taken?
Raloxifene should be taken as 1 tablet once daily.
If I am using this medication for osteoporosis is there anything important I should know?
Yes. Evista or raloxifene, if used for the prevention or treatment of osteoporosis, should be taken with a supplemental calcium/vitamin D product if you aren’t getting a sufficient amount though diet alone.
For more information on Evista (raloxifene), check out the Evista package insert here.